Uniquity Bio Welcomes Jason Moore as Senior Vice President, Regulatory & Quality
Appointment Strengthens Company’s Capabilities Ahead of Phase II Study Completion and Potential Late-Stage Development
Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation and backed by Blackstone Life Sciences, today announced the appointment of Jason Moore as Senior Vice President, Regulatory & Quality. A seasoned biopharma executive, Mr. Moore has led drug development programs across multiple therapeutic areas and every stage of clinical development, with a history of executing programs for regulatory and commercial success. He most recently served as the Senior Vice President of Regulatory Affairs & Quality Assurance at Nefro Avillion Clinical Development.
Mr. Moore is a strategic addition to Uniquity’s leadership team as the company readies for the potential late-stage development of its lead asset, solrikitug. Solrikitug is a highly potent monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), with topline data readouts expected this year from its Phase II trials in asthma, chronic obstructive pulmonary disease (COPD), and eosinophilic esophagitis (EoE).
